Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trial

Journal:

Nature Medicine

Published:

2025-05-12

DOI:

10.1038/s41591-025-03679-7

Affiliations:

5

Authors:

10

Go to article

Institutions	Authors	Share
AbbVie, United States of America (USA)	6.000000	0.60
Mayo Clinic - Scottsdale, United States of America (USA)	2.000000	0.20
MedStar Georgetown University Hospital, United States of America (USA)	1.000000	0.10
NIHR / Wellcome Trust King's Clinical Research Facility (CRF), United Kingdom (UK)	0.500000	0.05
University of California, Los Angeles (UCLA), United States of America (USA)	0.500000	0.05

Interested in Neurosciences?